Cargando…

Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only

BACKGROUND: The nature and extent of inflammation seen in multiple sclerosis (MS) varies throughout the course of the disease. Changes seen in CD4+ T-helper cells in relapsing–remitting (RR) MS and secondary progressive (SP) MS might differ qualitatively and/or quantitatively. OBJECTIVE: The objecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalra, S, Lowndes, C, Durant, L, Strange, RC, Al-Araji, A, Hawkins, Clive P, Curnow, S John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990617/ https://www.ncbi.nlm.nih.gov/pubmed/32064115 http://dx.doi.org/10.1177/2055217319899695

Ejemplares similares

Oral available agents in the treatment of RRMS
por: Aupérin, Thierry
Publicado: (2013)

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study
por: Dobreanu, Minodora, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Distinct binding properties of TIAR RRMs and linker region
por: Kim, Henry S., et al.
Publicado: (2013)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

Cortical Pathology in RRMS: Taking a Cue from Four Sisters
por: Calabrese, Massimiliano, et al.
Publicado: (2012)

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017)

Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization
por: De Stefano, Nicola, et al.
Publicado: (2021)

The SRSF1 linker induces semi-conservative ESE binding by cooperating with the RRMs
por: Cho, Suhyung, et al.
Publicado: (2011)

Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS
por: Muthuraman, Muthuraman, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD
por: Samaraweera, Amal P.R., et al.
Publicado: (2018)

Distributed causality in resting-state network connectivity in the acute and remitting phases of RRMS
por: Wu, Lin, et al.
Publicado: (2020)

Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients
por: Balasa, Rodica, et al.
Publicado: (2022)

Evidence for cooperative tandem binding of hnRNP C RRMs in mRNA processing
por: Cieniková, Zuzana, et al.
Publicado: (2015)

EDSS and infratentorial white matter lesion volume are considered predictors of fatigue severity in RRMS
por: Ezzeldin, Mohammed Y., et al.
Publicado: (2023)

Structural insights into the targeting of mRNA GU-rich elements by the three RRMs of CELF1
por: Edwards, John M., et al.
Publicado: (2013)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Lost in Classification: Lower Cognitive Functioning in Apparently Cognitive Normal Newly Diagnosed RRMS Patients
por: Pitteri, Marco, et al.
Publicado: (2019)

What Evidence Is There That Gadobutrol Causes Increasing Signal Intensity within the Dentate Nucleus and Globus Pallidus on Unenhanced T1W MRI in Patients with RRMS?
por: Agris, Jacob, et al.
Publicado: (2015)

Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease
por: Singh, Kritika, et al.
Publicado: (2022)

CCR6(+) Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells
por: Restorick, S.M., et al.
Publicado: (2017)

A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study
por: Mattioli, Flavia, et al.
Publicado: (2015)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study
por: Lu, Zhengjuan, et al.
Publicado: (2020)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
por: Steingo, Brian, et al.
Publicado: (2020)

SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting
por: Zecca, Chiara, et al.
Publicado: (2020)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS
por: Machcińska, Maja, et al.
Publicado: (2022)

A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD
por: Chen, Bo, et al.
Publicado: (2021)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens
por: Rodi, Maria, et al.
Publicado: (2016)

HuR biological function involves RRM3-mediated dimerization and RNA binding by all three RRMs
por: Pabis, Marta, et al.
Publicado: (2019)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
por: Feng, Jenny, et al.
Publicado: (2019)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jc4dom118tqh2ksgtulr6o6n66